
OmniAb Inc (OABI) Stock Forecast & Price Target
OmniAb Inc (OABI) Analyst Ratings
Bulls say
OmniAb Inc. demonstrates a robust outlook due to its significant progress in advancing both its proprietary portfolio and strategic partnerships, reflecting strong demand for its innovative therapeutic antibody discovery technologies. The anticipated 4Q24 financials suggest improved revenues of $12.3 million and a reduced net loss, indicating effective management of operational expenditures while expanding its discovery efforts. Furthermore, the continued expansion through new license agreements underlines OmniAb's commitment to building a diversified and technology-driven portfolio, which positions the company favorably for future growth and potential share price appreciation.
Bears say
OmniAb experienced a significant decline in revenue for 3Q24, reporting $4.2 million compared to $5.5 million in the same quarter of the previous year, alongside a widening net loss of $16.4 million. The downward trend in revenue is primarily attributed to lower license and service revenues, along with missed expectations of $10.9 million. Furthermore, projections for full-year revenues have decreased to $27.9 million from $34.2 million in 2023, highlighting challenges in securing adequate funding, achieving successful clinical trial outcomes, and commercial traction for its therapeutics.
This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares